Who
Jason A. Keyes
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, BlossomHill Therapeutics; Director, Actuate Therapeutics; Chief Financial Officer, Equillium; Director, Sesen Bio; EVP, Chief Financial Officer, Orexigen Therapeutics.
In numbers
- Trades disclosed
- 68
- Buys
- 1
- Sells
- 17
- Bought
- $22K
- Sold
- $384K
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 12 Jul 2016
- Last trade
- 10 Aug 2026
- Last filed
- 10 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill TherapeuticsBiotechnology | SEC FORM 4 Bought | $11K700 at $16.00 | filing |
| 10 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill TherapeuticsBiotechnology | SEC FORM 4 Bought | $11K700 at $16.00 | filing |
| 6 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —56,746 at $0.00 | filing |
| 6 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —56,746 at $0.00 | filing |
| 21 May 2026filed 22 May 2026 | ACTU Actuate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 21 May 2026filed 22 May 2026 | ACTU Actuate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 22 May 2025filed 23 May 2025 | ACTU Actuate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code D | —70,000 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code D | —90,000 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code D | —100,000 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code D | —125,000 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code D | —175,000 | filing |
| 23 Jan 2025filed 24 Jan 2025 | EQ EquilliumBiotechnology | SEC FORM 4 Sold | $6,50010,000 at $0.65 | filing |
| 2 Jan 2025filed 6 Jan 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 10 Dec 2024filed 6 Jan 2025 | EQ EquilliumBiotechnology | SEC FORM 4 Code A | $8,10015,000 at $0.54 | filing |
News
BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung CancerBLSM · manilatimes.net · 22 Oct 2026
0 headlines in the last 90 days name Jason A. Keyes; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.